Balstilimab

FDA Grants Fast Track designation for BOT/BAL in metastatic, refractory colorectal cancer (CRC) patients who have failed 1st and 2nd line standard of care treatments Data from Phase 1 of BOT/BAL in refractory CRC showed durable ORR of 24% in patients with non-active liver metastases (NLM); Completed enrollment of randomized Phase 2 trial (n=230) Clinical data sets path for expansion opportunities in pancreas, lung, neoadjuvant CRC, and melanoma LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today provided a corporate update and reported financial results for the fourth quarter and full year 2023. “In 2023, Agenus made significant advances across our BOT/BAL development program. Our first target indication is metastatic, refractory colorectal cancer that is not MSI-H/dMMR, for which we are focused on pursuing accelerated approval,” said Garo Armen, Ph.D., Chief Executive Officer. “We are also pursuing multiple strategies to capitalize the company through this important path in our efforts to bring BOT and BOT/BAL to the forefront of solid tumor cancer treatment. Our vision is to maximize BOT's utility to benefit patients in combination with other immune therapies as well as current standards of care for patients with both early and late-stage tumors.” 2023 Highlights on Botensilimab Colorectal Cancer: Received Fast Track designation for patients with metastatic colorectal cancer that is not MSI-H/dMMR and who do not have liver metastases, and who were previously treated with standard combination chemotherapy, anti-VEGF and anti-EGFR if RAS wild type (“refractory MSS mCRC NLM”) Completed enrollment of patients with refractory MSS mCRC NLM in a Phase 1 (n=150) and randomized Phase 2 (n=230) in October 2023. Clinical data reported by Agenus in October 2023 revealed: Among the 70 efficacy evaluable ("EE") patients in the refractory MSS mCRC NLM treatment setting, a 24% RECIST v1.1 response rate was observed in those treated with the BOT/BAL combination. Based on literature review, the response rate in a similar population treated with standard of care therapies ranges from 1% to 6.1%1, 2. The 12-month overall survival (OS) rate is 74% with median OS not yet reached. Topline data from the ongoing Phase 2 study are expected in 2H 2024. The most common safety observations are immune-related diarrhea and colitis, which are managed in accordance with standard therapies. Grade 3 treatment related diarrhea/colitis occurred in approximately 14% of patients. Neoadjuvant CRC: Clinical data presented at ASCO-GI January 2024: In an investigator sponsored trial (IST) led by Dr. Pashtoon Kasi at Weill-Cornell Medicine, patients diagnosed with resectable localized colon or rectal cancer were treated with one dose of BOT and two doses of BAL approximately 4 weeks prior to planned surgery. After surgery, pathologic analysis reported significant tumor shrinkage. 3/3 patients (100%) with MSI-H CRC experienced major pathological responses (>90% tumor shrinkage) in less than 4 weeks, while 6/9 (67%) MSS CRC patients had tumor shrinkage of 50% or more. IST is expanding to 24 patients with an extended follow-up time (6-8 weeks); Agenus plans to prioritize neoadjuvant development and is evaluating study designs for subsequent pivotal trials. 2L Metastatic Pancreatic: In patients with metastatic pancreatic cancer who have failed or don’t respond to FOLFIRINOX (2L Pancreatic) and received treatment with BOT in combination with gemcitabine+nab-paclitaxel, significant tumor marker reductions were observed in 4 of 5 patients, all with liver metastases. Two (2) of the 4 patients achieved PRs at 16 weeks (target lesion reductions of 47% (confirmed) and -37% (pending confirmation). Two other patients showed stable disease at their first 8-week scan with tumor reductions of -20% and -13%. A Phase 2 randomized study is in progress, with preliminary data expected to be available mid-year. CTLA-4/PD-1 Relapsed Refractory Advanced Melanoma (“2L+ Melanoma”): Phase 1b expansion cohort in 2L+ Melanoma reported a 30% ORR and 60% disease control rate (n=10; 2/8 BOT responses and 1/2 BOT/BAL responses); all patients had failed anti-PD-1 therapy and 8/10 had failed both anti-PD-1/CTLA-4 therapy. In the Phase 2 study in 2L+ Melanoma, data from the fully enrolled BOT monotherapy arm and a cohort of patients on BOT/BAL (n=30) are anticipated in 2H2024. Refractory Non-Small Cell Lung Cancer (NSCLC): In the PD(L)-1 refractory cohort, a 56% ORR and an 89% disease control rate were observed in patients treated with the BOT/BAL combination (n=9). In a TKI-refractory cohort, 2 out of 7 patients experienced complete confirmed objective responses after treatment with BOT/BAL*. Advanced Sarcomas: Updated findings from a Phase 1b study of 41 efficacy evaluable patients treated with BOT/BAL showed durable responses with an ORR of 20%, a median response duration of 19.4 months (iRECIST), and a 6-month progression-free survival rate of 40%. A higher ORR was observed by dose level, with 29% at 2 mg/kg BOT compared to 15% at 1 mg/kg BOT. Refractory Ovarian: In a total of 24 evaluable patients treated with BOT/BAL, with a median of four prior lines of therapy, an overall response rate of 33% was observed. The disease control rate was 67% and the median Duration of Response (DOR) was not yet reached. Finance $25 million milestone payment from BMS triggered by the commencement of a Phase 2 study with BMS-986442 in December 2023. Advancing in our discussions on monetizing non-strategic assets, royalty monetization, and project financing, with the potential to yield $100-200 million in cash proceeds. Currently we are in active discussions with several potential biopharma partners for potential co-development and co-commercialization of BOT/BAL. Fourth Quarter and Full Year 2023 Financial Results For the year ended December 31, 2023, we recognized revenue of $156 million and incurred a net loss of $257 million, or $0.69 per share. For the fourth quarter ended December 31, 2023, we recognized revenue of $84 million and incurred a net loss of $49 million or $0.13 per share. Revenue primarily includes revenue under our collaboration agreements, including milestones achieved, and revenue related to non-cash royalties earned. We ended the year with a $76.1 million cash balance; subsequent to which in January 2024 we received the $25 million milestone payment from BMS triggered by the commencement of a Phase 2 study with BMS-986442, the AGENUS discovered TIGIT bispecific antibody. Additionally, we've progressed in monetizing non-strategic assets and future milestones and royalties from ongoing partnerships. These efforts are expected to yield significant cash proceeds by mid 2024. Accordingly, we anticipate being funded through 2024. In parallel, we're pursuing potential partnership discussions with several biopharmaceuiticsl parties to further expand our cash resources. December 31, 2023 2022 Cash, cash equivalents and short-term investments $ 76,110 $ 193,358 Three months ended December 31, Year ended December 31, 2023 2022 2023 2022 Revenues, research and development $ 30,249 $ 3,755 $ 38,764 $ 16,975 Revenues, non-cash royalty 53,038 18,284 114,572 45,285 Revenues, royalty sales milestone - - - 25,250 Revenues, other 514 6,347 2,978 10,514 Total Revenue 83,801 28,386 156,314 98,024 Research and development expenses 66,723 53,279 234,569 186,691 General and administrative expenses 21,177 25,036 78,739 81,007 Cost of service revenue 260 7,693 3,111 10,568 Other income (193 ) (3,918 ) (2,663 ) (10,944 ) Non-cash interest expense 44,574 18,326 100,551 62,955 (Gain) loss related to debt - 1,937 - (782 ) Non-cash contingent consideration fair value adjustment (158 ) 135 (556 ) (815 ) Net loss $ (48,582 ) $ (74,102 ) $ (257,437 ) $ (230,656 ) Net loss per share attributable to Agenus Inc. common stockholders $ (0.13 ) $ (0.24 ) $ (0.69 ) $ (0.78 ) Cash used in operations $ 40,590 $ 47,338 $ 224,202 $ 175,373 Non-cash operating expenses $ 56,455 $ 32,777 $ 139,015 $ 96,286 Conference Call Date: March 14th, 2024, 8:30 a.m. ET To access dial-in numbers, please register here. Conference ID: 73242 Webcast A live webcast and replay of the conference call will be accessible on the company’s website at and via . References 1 Prager et. al NEJM 2023 2 Grothey et al. Lancet 2013 * Investigator reported, subject to change About Botensilimab Botensilimab is an investigational multifunctional anti-CTLA-4 immune activator (antibody) designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to "cold" tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses. Approximately 900 patients have been treated with botensilimab in phase 1 and phase 2 clinical trials. Botensilimab alone, or in combination with Agenus’ investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. For more information about botensilimab trials, visit with the identifiers NCT03860272, NCT05608044, NCT05630183, and NCT05529316. About Agenus Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels. Forward-Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding a its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "forecasts," "estimates," "will," “establish,” “potential,” “superiority,” “best in class,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission and available on our website at . Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

MiNK-215 Eradicated Tumor Cells in Human Organoid MSS Colorectal Cancer Liver Metastases ModelNEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced the presentation of preclinical data from MiNK-215, an IL-15 armored FAP-targeting CAR-iNKT cell therapy, at the upcoming AACR Meeting, to be held April 5 – 10, 2024 in San Diego, CA. MiNK-215 is an investigational IL-15 armored FAP-targeting CAR-iNKT cell therapy being studied in human organoid models as a novel approach for patients with colorectal cancer (CRC) liver metastases. The liver acts an essential filter for foreign substances that enter the body through the intestinal tract, shutting down the cytotoxic T cell responses against foreign antigens. This includes the tumor antigens that present due to liver metastases, as the liver shuts down the anti-cancer T cell response. Consequently, liver metastases pose a significant challenge for current pharmacological treatments, including immune checkpoint inhibitors (ICIs). iNKT cells offer promise in overcoming this immune barrier, given their natural ability to reside in and migrate to the liver. The liver has the largest number of iNKT cells as compared to any other organ and iNKT cells are drawn to CD1d-expressing cells, a prevalent cell type in the liver. In human organoid models of CRC with liver metastases, MiNK-215 potently enhanced tumor killing by T cells and was associated with depletion of immune suppressive FAP-expressing stellate cells and increased CD8+ T cell infiltration. This allows the body to mount a much stronger T-cell response against the liver metastases, which can then be further enhanced by adding ICIs, like Agenus’ botensilimab/balstilimab. “Liver metastases, especially in MSS-CRC, have remained a critical challenge in cancer care and represent a setting where novel therapeutic approaches are urgently needed to improve outcomes for patients,” said Dr. Marc van Dijk, Chief Scientific Officer at MiNK. “These first-of-a-kind data underscore the unique potential of iNKT cells to overcome the refractory liver microenvironment. We are proud to partner with Agenus on these innovative models to aid the design of clinical studies that can evaluate the synergy of allogeneic iNKT cells and botensilimab/balstilimab to expand benefit for patients.” Presentation Details: Abstract Title: MiNK-215, an IL-15 armored FAP-targeting CAR iNKT cell therapy, effectively treats human organoid models of treatment-refractory MSS colorectal cancer (CRC) liver metastases Abstract Number: 1331 Presenting Author: Shanmugarajan Krishnan Session: CAR-NK, NK Engagers, and NK Modulators Presentation Session Date and Time: Monday April 8, 2024, 9:00 a.m. – 12:30 p.m. PST Data presented at the conference will be available to view in the publications section of the MiNK website (https://minktherapeutics.com/publications/) following the AACR Meeting. References: Gu, X., et al. Front Immunol. 2022Chen, Y., et al. Cell Mol Immunol. 2021 About MiNK Therapeutics MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels. Forward Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic and curative potential of MiNK-215, including the mechanism of action, potency and safety, interim or top-line data, including statements regarding preclinical data, the anticipated benefits of MiNK-215 and clinical development plans and timelines. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Investor Contact917-362-1370investor@minktherapeutics.com Media Contact781-674-4428communications@minktherapeutics.com